newsfilter
← Latest News
GlobeNewswire·

Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference

EDIT
  • The U.S. Patent and Trademark Office reaffirmed a prior Patent Trial and Appeal Board decision favoring the Broad Institute in a CRISPR/Cas9 patent interference case involving human cells.
  • This ruling marks the third favorable decision by the PTAB determining that the Broad Institute was the first to invent CRISPR/Cas9 gene editing in eukaryotic cells.
  • The decision follows a May 2025 U.S. Court of Appeals for the Federal Circuit ruling that vacated-in-part the previous PTAB decision.
  • Editas Medicine holds exclusive licenses to the Broad Institute's Cas9 patent estate for human medicines and its Cas12a patent estate.
  • CEO Gilmore O'Neill stated the outcome reinforces confidence in Editas Medicine's intellectual property while advancing therapies like EDIT-401.
  • EDIT-401 is an experimental one-time therapy that achieved a greater than 90 percent mean LDL cholesterol reduction in non-human primates.
  • The University of California, University of Vienna, and Emmanuelle Charpentier retain the right to appeal the PTAB decision to the Federal Circuit.
  • Other in-licensed patents covering CRISPR/Cas12a and CRISPR/Cas9 not at issue in this interference remain unaffected by the decision.
  • Editas Medicine holds foundational intellectual property covering both CRISPR/Cas12a and CRISPR/Cas9 gene editing in human cells across multiple jurisdictions including the U.S., Europe, China, and Japan.